Potassium Blood Pressure Meta-analysis: What the Evidence Says

Quick Answer

Potassium Blood Pressure Meta-analysis has 4 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 4 systematic review.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• This phenotype is associated with higher risks of stroke, heart failure, chronic kidney disease, and death. [Falodia Rahul (2026); evidence level 1]
• In the phase 2 BrigHTN trial, baxdrostat reduced seated systolic BP by 8-11 mmHg versus placebo at 12 weeks in resistant hypertension, without adrenocortical insufficiency or serious drug-related events. [Falodia Rahul (2026); evidence level 1]
• A meta-analysis of 91 studies from 1991-2017 with over 3 million treated hypertensive patients found true-RH prevalence to be 10.3%.The pathophysiology of RH is multifactorial and not fully understood. [Kamrul-Hasan A.B.M. (2026); evidence level 1]
• Excess aldosterone promotes inflammation, vascular changes, and tissue fibrosis linked to cardiometabolic diseases.Due to its high prevalence as a cause of poor BP control, current RH guidelines recommend MRAs after 3 antihypertensives, though side effects, especially antiandrogenic ones, often limit use.The emerging role of aldosterone-targeted therapies, including ASIs, is promising. [Kamrul-Hasan A.B.M. (2026); evidence level 1]
• Various factors may contribute to reduced treatment adherence, notably insufficient knowledge, which is a key factor that, alongside considerations such as attitude and satisfaction, affects adherence. [Sarmadi Sogand (2026); evidence level 1]
• Failure to comply with dietary guidelines and fluid management in these patients may cause elevated blood pressure, fluid retention, edema, hyperkalemia, hyperphosphatemia, and a heightened risk of cardiovascular disease, potentially leading to recurrent hospitalizations and mortality. [Sarmadi Sogand (2026); evidence level 1]
• Data from large potential cohorts in the general population and in treated hypertensive patients suggest that hypertension is an independent risk factor for adverse renal outcomes, with a close relationship between the level of blood pressure and the incidence and progression of CKD. [Bhuiya N M Mahmudul Alam (2026); evidence level 1]
• Conversely, CKD is an independent risk factor for the development of hypertension and cardiovascular disease. [Bhuiya N M Mahmudul Alam (2026); evidence level 1]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. For potassium blood pressure meta-analysis, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Falodia Rahul (2026). Efficacy and Safety of Baxdrostat for Hypertension: A Systematic Review and Meta‐Analysis of Three Phase 2/3 Randomized Controlled Trials. DOI: 10.1002/clc.70391. PMCID: PMC13288374. PMID: 42334050. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13288374/
• Kamrul-Hasan A.B.M. (2026). Safety and efficacy of lorundrostat, an aldosterone synthase inhibitor, in patients with uncontrolled hypertension: A systematic review and meta-analysis. DOI: 10.1097/MD.0000000000049158. PMCID: PMC13246067. PMID: 42260805. License: https://creativecommons.org/licenses/by-nc/4.0/ Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC) Thi.... https://pmc.ncbi.nlm.nih.gov/articles/PMC13246067/
• Sarmadi Sogand (2026). The effect of nutrition education interventions on dialysis patients’ outcomes: a systematic review and meta-analysis. DOI: 10.1080/07853890.2026.2660389. PMCID: PMC13104004. PMID: 42015790. License: https://creativecommons.org/licenses/by-nc/4.0/ http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access.... https://pmc.ncbi.nlm.nih.gov/articles/PMC13104004/
• Bhuiya N M Mahmudul Alam (2026). Effects of Aliskiren Monotherapy on Chronic Kidney Disease: A Systematic Review and Meta‐Analysis of Blood Pressure and Urinary Protein Excretion Outcomes. DOI: 10.1111/jch.70237. PMCID: PMC13097542. PMID: 41863844. License: https://creativecommons.org/licenses/by-nc/4.0/ http://creativecommons.org/licenses/by-nc/4.0/ This is an open access.... https://pmc.ncbi.nlm.nih.gov/articles/PMC13097542/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.